$6.22
2.35% day before yesterday
Nasdaq, Dec 27, 10:01 pm CET
ISIN
CA31447P1009
Symbol
FENC
Sector
Industry

Fennec Pharmaceuticals Inc. Stock price

$6.22
+0.21 3.49% 1M
+0.07 1.14% 6M
-5.00 44.56% YTD
-5.32 46.10% 1Y
+1.90 43.98% 3Y
-0.01 0.08% 5Y
+3.96 175.22% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.15 2.35%
ISIN
CA31447P1009
Symbol
FENC
Sector
Industry

Key metrics

Market capitalization $170.60m
Enterprise Value $160.06m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 6.76
EV/Sales (TTM) EV/Sales 3.24
P/S ratio (TTM) P/S ratio 3.46
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 278.09%
Revenue (TTM) Revenue $49.35m
EBIT (operating result TTM) EBIT $1.68m
Free Cash Flow (TTM) Free Cash Flow $23.69m
Cash position $40.32m
EPS (TTM) EPS $-0.10
P/E forward negative
P/S forward 3.93
EV/Sales forward 3.69
Short interest 11.18%
Show more

Is Fennec Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Fennec Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Fennec Pharmaceuticals Inc. forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Fennec Pharmaceuticals Inc. forecast:

Buy
100%

Financial data from Fennec Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
49 49
278% 278%
100%
- Direct Costs 3.20 3.20
385% 385%
6%
46 46
272% 272%
94%
- Selling and Administrative Expenses 44 44
51% 51%
90%
- Research and Development Expense 0.29 0.29
107% 107%
1%
1.68 1.68
110% 110%
3%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 1.68 1.68
110% 110%
3%
Net Profit -1.13 -1.13
94% 94%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Fennec Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fennec Pharmaceuticals Inc. Stock News

Neutral
GlobeNewsWire
9 days ago
~ PEDMARQSI®  (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children and young people (1 month-17 years of age) ~
Neutral
GlobeNewsWire
10 days ago
~ $13 Million Convertible Debt Repayment from Available Cash ~ ~ Elimination of Approximately $1.5 Million in Annual Interest Expense and Potential Equity Overhang of Approximately 1.6 Million Shares ~ RESEARCH TRIANGLE PARK, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the early repayment of $13...
Neutral
GlobeNewsWire
17 days ago
RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the virtual H.C. Wainwright @ Home Fireside Chat Series taking place on Monday, December 16, 2024 at 11:00 a.m. ET.
More Fennec Pharmaceuticals Inc. News

Company Profile

Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Head office Canada
CEO Jeffrey Hackman
Employees 29
Founded 1996
Website www.fennecpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today